Asthma control and its predictors in Ethiopia: Systematic review and meta-analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
27
11
2020
accepted:
30
12
2021
entrez:
13
1
2022
pubmed:
14
1
2022
medline:
19
2
2022
Statut:
epublish
Résumé
Determining the status of asthma control and identifying risk factors for poor asthma control is a key strategy for curbing the negative health impacts and the financial burden of the disease. Therefore, this review was aimed to determine the rate of asthma control and assess the predictors of uncontrolled asthma in Ethiopia. PubMed, Web of Science, and Google Scholar searches were performed using key terms; "asthma, bronchial asthma, control, controlled, uncontrolled and Ethiopia" up to October 16, 2020. University repositories were also searched to retrieve gray literature. The results were presented as a prevalence rate with a 95% confidence interval (CI). Subgroup analysis and meta-regression were performed to identify the sources of heterogeneity in the outcomes. From 1,388 patients, based on the Global Initiative for Asthma (GINA) symptom control, the rate of the uncontrolled asthma was 45.0% (95% CI 34.0% - 56.0%) with a considerable heterogeneity between the studies; (I2: 94.55, p< 0.001). About 19.0% (95% CI 10.0% - 29.0%); (I2: 96.04, p< 0.001) of the asthma patients had a well-controlled asthma. Moreover, 36.0% (95% CI 22.0% - 50.0%), (I2: 97.11, p< 0.001) of patients had a partly controlled asthma. Similarly, based on the asthma control test (ACT), the rate of well-controlled asthma was 22.0% (95% CI 3% - 42.0%), with considerable heterogeneity between the studies; (I2: 97.75, p< 0.001). The most frequent predictors of uncontrolled asthma were incorrect inhalation techniques, frequent SABA use, moderate/severe persistent asthma, history of exacerbations, presence of comorbidities, use of oral corticosteroids, and irregular follow-up. The rate of uncontrolled asthma in Ethiopia was high. Several factors are associated with uncontrolled asthma. Comprehensive asthma educations at each follow-up visit should be strengthened to minimize the morbidity and the cost of uncontrolled asthma.
Sections du résumé
BACKGROUND
Determining the status of asthma control and identifying risk factors for poor asthma control is a key strategy for curbing the negative health impacts and the financial burden of the disease. Therefore, this review was aimed to determine the rate of asthma control and assess the predictors of uncontrolled asthma in Ethiopia.
METHODS
PubMed, Web of Science, and Google Scholar searches were performed using key terms; "asthma, bronchial asthma, control, controlled, uncontrolled and Ethiopia" up to October 16, 2020. University repositories were also searched to retrieve gray literature. The results were presented as a prevalence rate with a 95% confidence interval (CI). Subgroup analysis and meta-regression were performed to identify the sources of heterogeneity in the outcomes.
RESULTS
From 1,388 patients, based on the Global Initiative for Asthma (GINA) symptom control, the rate of the uncontrolled asthma was 45.0% (95% CI 34.0% - 56.0%) with a considerable heterogeneity between the studies; (I2: 94.55, p< 0.001). About 19.0% (95% CI 10.0% - 29.0%); (I2: 96.04, p< 0.001) of the asthma patients had a well-controlled asthma. Moreover, 36.0% (95% CI 22.0% - 50.0%), (I2: 97.11, p< 0.001) of patients had a partly controlled asthma. Similarly, based on the asthma control test (ACT), the rate of well-controlled asthma was 22.0% (95% CI 3% - 42.0%), with considerable heterogeneity between the studies; (I2: 97.75, p< 0.001). The most frequent predictors of uncontrolled asthma were incorrect inhalation techniques, frequent SABA use, moderate/severe persistent asthma, history of exacerbations, presence of comorbidities, use of oral corticosteroids, and irregular follow-up.
CONCLUSION
The rate of uncontrolled asthma in Ethiopia was high. Several factors are associated with uncontrolled asthma. Comprehensive asthma educations at each follow-up visit should be strengthened to minimize the morbidity and the cost of uncontrolled asthma.
Identifiants
pubmed: 35025962
doi: 10.1371/journal.pone.0262566
pii: PONE-D-20-37357
pmc: PMC8758033
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Anti-Asthmatic Agents
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0262566Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Croat Med J. 2013 Dec;54(6):519-31
pubmed: 24382846
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
BMC Res Notes. 2019 Jan 14;12(1):15
pubmed: 30642378
Arch Bronconeumol. 2010 Jul;46(7):358-63
pubmed: 20227808
Indian J Pharmacol. 2017 Jan-Feb;49(1):110-115
pubmed: 28458433
Int J Tuberc Lung Dis. 2014 Mar;18(3):371-6
pubmed: 24670578
PLoS One. 2019 Apr 18;14(4):e0215530
pubmed: 30998727
Eur Respir Rev. 2009 Jun;18(112):105-12
pubmed: 20956130
Bull World Health Organ. 2005 Jul;83(7):548-54
pubmed: 16175830
ERJ Open Res. 2020 Oct 19;6(4):
pubmed: 33123561
Eur Respir J. 2020 Apr 16;55(4):
pubmed: 31949111
Ther Adv Respir Dis. 2016 Dec;10(6):507-517
pubmed: 27595644
J Allergy Clin Immunol. 2007 Dec;120(6):1360-7
pubmed: 17981317
Lancet Respir Med. 2015 Feb;3(2):159-170
pubmed: 25680912
J Asthma. 2010 Apr;47(3):257-62
pubmed: 20210612
Respir Med. 2014 Feb;108(2):271-7
pubmed: 24406243
Psychiatry J. 2018 Aug 26;2018:5934872
pubmed: 30225243
JAMA. 1990 Oct 3;264(13):1719-20
pubmed: 2398613
Pulm Med. 2020 Jul 28;2020:5389780
pubmed: 32802503
J Asthma. 2010 Jun;47(5):557-62
pubmed: 20560829
J Investig Allergol Clin Immunol. 2020;30(4):264-271
pubmed: 31283523
Allergy Asthma Clin Immunol. 2018 Jul 10;14:29
pubmed: 30002684
Ann Allergy Asthma Immunol. 2007 Feb;98(2):146-52
pubmed: 17304881
Respir Care. 2014 Feb;59(2):223-30
pubmed: 23882109
Respir Res. 2021 Apr 16;22(1):108
pubmed: 33863317
BMC Pulm Med. 2018 Apr 24;18(1):61
pubmed: 29699541
J Allergy Clin Immunol. 2006 Feb;117(2):351-8
pubmed: 16461136
Asthma Res Pract. 2017 Jan 6;3:1
pubmed: 28078100
NPJ Prim Care Respir Med. 2014 Jun 12;24:14009
pubmed: 24921985
Allergy. 2013 Nov;68(11):1463-6
pubmed: 24117970
J Clin Med Res. 2019 Dec;11(12):807-817
pubmed: 31803325
Allergy Asthma Clin Immunol. 2013 Mar 06;9(1):8
pubmed: 23510684
J Bras Pneumol. 2013 Sep-Oct;39(5):532-8
pubmed: 24310625
J Asthma. 2019 Sep;56(9):1016-1025
pubmed: 30252543
J Asthma. 2014 Sep;51(7):769-78
pubmed: 24697738
Eur Respir Rev. 2012 Mar 1;21(123):66-74
pubmed: 22379176
Respir Med. 2009 Dec;103 Suppl 2:S12-20
pubmed: 20122624
J Allergy Clin Immunol. 2007 Jun;119(6):1454-61
pubmed: 17481716
BMC Res Notes. 2017 Nov 6;10(1):558
pubmed: 29110731
Ann Thorac Med. 2019 Apr-Jun;14(2):148-154
pubmed: 31007767
Respir Med. 2013 Nov;107(11):1659-66
pubmed: 24045118
PLoS One. 2020 May 12;15(5):e0232621
pubmed: 32396562
Scientifica (Cairo). 2013;2013:549252
pubmed: 24455432
Ethiop J Health Sci. 2014 Jan;24(1):49-58
pubmed: 24591799
BMJ Open. 2016 Dec 8;6(12):e011458
pubmed: 27932337
Thorax. 2019 Nov;74(11):1020-1030
pubmed: 31278168
J Asthma. 2020 Feb;57(2):113-122
pubmed: 30915868
Prim Care Respir J. 2009 Dec;18(4):279-86
pubmed: 19455269
BMC Pulm Med. 2020 Feb 21;20(1):48
pubmed: 32085726
Curr Med Res Opin. 2009 Oct;25(10):2523-31
pubmed: 19708765
PLoS One. 2020 Oct 6;15(10):e0239665
pubmed: 33022006
Respir Med. 2018 May;138:64-73
pubmed: 29724395
BMC Res Notes. 2019 Aug 20;12(1):525
pubmed: 31429799
J Occup Environ Med. 2003 Dec;45(12):1234-46
pubmed: 14665809
J Allergy Clin Immunol Pract. 2018 Nov - Dec;6(6):1953-1959
pubmed: 29454162
Curr Opin Allergy Clin Immunol. 2012 Feb;12(1):39-41
pubmed: 22157151
Can Respir J. 2019 Aug 1;2019:6934040
pubmed: 31467621